I went into a sales job first actually within Janssen. I went into R&D for a few years and then followed a product through into marketing. I became a board member, managed a business as a managing director of small business in the UK, part of J&J, and then did a few jobs, both European jobs and also a job in the US setting up our virology franchise. And then was asked to sort of look after half the region that I'm now responsible for and then subsequently took over the whole region about close to three years ago now. I'm a sponsor of our sustainability group globally for the pharmaceutical group. I chair our corporate citizens trust which is our corporate giving in Europe, cross sector actually. I'm an advisory member of Women's Leadership Panel, HBA, and all of those are quite dear to my heart those topics as well. So the business was that is really great. I loved my job. I loved my job. You'll have seen in the press recently that Janssen has formed a lot of external collaborations recently. We've really increased the number of collaborations we've got with universities, with small biotech companies. We've set up three innovation centres globally recently in California, Boston, London, and hopefully we'll be opening one up in China soon. And these are really aimed at fostering collaboration between small biotech between their university research establishments and ourselves. The mantra really from my head of R&D is we'll follow the great science wherever it is. There's also collaboration between pharmaceutical companies and I think I sense that the industry at the moment is more open for collaboration than it ever has been. There's a lot of sharing of science, particularly in areas for example like Alzheimer's which is a really tricky subject to try and get out and to innovate in. Now I think it's absolutely correct that the industry has to demonstrate value for money. And we will do that by bringing as J&J and Janssen, we'll do that by bringing high innovation in areas of high on met need. I think the industry does need to try to work to say can there at least be some sort of common HTA assessment, not a common pricing reimbursement framework. Because each country will be different in that respect. But to assess drugs in the same way, to have the same comparator for example, it's not the same in all countries right now. Germany for example is being really tough on what comparator is needed for some of these compounds. So there are two things that we've been discussing recently. One is transparency of Dr. Payments and the other is transparency of clinical trial data. So with the Dr. Payments now we agreed at the general assembly that they will be transparency on that and there will be more news coming out on that in the future. And also on data transparency as well, the industry absolutely understands the general public's requirement for us to be more transparent on the data. And that too we're making progress as a company on our website, we're quite clear about what our transparency policy is right now. And I think you'll have a coalescing of the industry move that topic forward because it gets in the way sometimes of being able to have open dialogue and being a trusted industry. And I think people think things are being withheld or hidden and I think the sooner that that transparency can be made the better. Every protocol that's set up is lodged on a website clinicaltrials.gov. Every clinical research program ultimately will be public after approval of a product. So we'll be able to study reports, there's some discussion over at the moment but in general there will be more transparency of data as long as it's not compromising the commercial aspects and competitiveness. But I really think that it will break down some barriers if the industry is seen to be more transparent in that area. And I'm quite sure that by the end of this year you'll see more transparency commitments from companies. There is a whole spectrum of activities that we have ongoing. One of the main things is that we help with health literacy and we work more with societies and countries to help educate and build infrastructure. So it's not just about putting money in for various projects, it's about enabling communities and societies to move along that journey of setting up healthcare infrastructure and then delivering better healthcare. But then the other part is our access activities around some of the products that we've researched. So for example in HIV we have waved our IP rights on Duronneville which is one of our products in Africa so that it makes it easier for other sort of parties to manufacture so that improves the access. Now these are because people in our industry care about societies being decimated by those diseases and it's not a precursor to something else. It's pure social responsibility on behalf of corporations such as J&J. I think the advice to myself might be, you know, don't underestimate what you can do. I see a lot of young women who, you know, aren't really confident enough in their own ability. And I think it can hold women back to a certain extent. I think that that's advice I'd like to give to people like myself, you know, like I was starting off a career, be confident and don't underestimate what you can do and how well you can do.